Lacerta Bio is a business development consultancy specializing in identifying, assessing, negotiating, and closing licensing and partnership opportunities for the pharmaceutical, biotechnology, and drug delivery industries.
We also work with and support internal business development teams with market research, competitive intelligence, financial modeling, and other support services.
In November, 2014, we announced a merger with Copenhagen-based Ventac Partners. The combination of Lacerta Bio and Ventac Partners will dramatically increase the types of services we can offer our clients, as well as expand our geographic reach.
If you need assistance finding or assessing business development and/or partnership opportunities, contact us at firstname.lastname@example.org.
Would You Like To Expand Your Business Into China? Or Perhaps You Seek An Investor or Development Partner? China is a large and growing opportunity for Western life science companies, as: Life Science in China is Booming – China’s life science industry has been growing at more than 20%+ per year, and is expect toRead More»
Lacerta Bio is pleased to represent the opportunity to in-license an innovative, approved parenteral formulation of diclofenac for acute / postoperative pain. While parenteral diclofenac products are available in a number of markets, our client’s formulation is clinically proven to have superior safety and efficacy characteristics. Key product benefits over the currently marketed product include:Read More»
Lacerta Bio is pleased to represent the opportunity to in-license an innovative, approved topical formulation of diclofenac for pain. While topical diclofenac products are available in a number of markets, our client’s formulation is clinically proven to have superior safety and efficacy characteristics. This topical diclofenac has a number of advantages over available topical diclofenacRead More»
The July/August issue of Drug Development and Delivery has an extensive report on the business and science of formulation and drug delivery. The report is based on the data in the PharmaCircle database.
The report is divided into various “Top Ten” categories, such as Ten Notable Drug Delivery Technologies of 2014, Transactions, etc., etc.
The report is rather lengthy, and we recommend a closer read (a free PDF version is available if you are not already a subscriber).
Based on our read, here are few items are of interest:
Just Because You Can…: Drug delivery and reformulation is like a pallet of innumerable colors. Give a good drug delivery expert a drug and he can come up with any number of ways to deliver that drug, or to enhance its PK profile.
However, just because something like this can be done does not mean that it should be done. In other words, not every reformulation or drug delivery play has a solid commercial rationale behind it.
The authors of this report note a few examples where it will be a challenge for some companies to generate significant sales, even with an approved product in hand.
Big Pharma Is Here To Stay: While our industry’s press is obsessed with the success and “flops” of new chemical entities, Big Pharma is very well represented in this report.
Scanning the pages, companies such as Roche, GSK, Biogen, and many others are represented.
In many cases, these multinational companies are using drug delivery technologies as line extensions. But for some, technologies represent new, novel ways to develop new products that fit specific markets.
Conversely, the authors note that small companies who develop products without market experience do so at their own peril.
Convenience…With PE Benefits: One of the criticisms of drug delivery and reformulation is that the only benefit is patient convenience.
This may be true in some cases, but we should also consider that convenience can increase compliance, and hence improve therapeutic benefits.
The authors have found several instances where delivery technologies provide an economic benefit as well, such as Amgen’s Neulasta Delivery Kit.
Again, the report makes for some interesting reading, and is a reminder of the benefits (and challenges) faced by companies in the drug delivery sector of our industry.
This question came up recently when I was describing one of our current clients as a “good” client. But what exactly is a “good” client? Three things come to mind. Responsiveness – There are many qualities that a good client possesses, but I think responsiveness comes to the top of the list, especially when we are
OK, so the new One-on-One Partnering system has not had a stellar introduction. We’re not here to complain about it, as this has been well covered on LinkedIn and elsewhere. But our experience this past month has reminded us of three key lessons which are important in any industry. Customers Rule Let’s make this
What follows is a true story. In 2013, we were engaged to out-license a series of Preclinical assets. One of these assets was in a therapeutic area which had very few Big Pharma participants. So, we did the obvious thing. We targeted multiple people across these Big Pharma companies around the World. One of them expressed